ImmunityBio Directors Sell $1.1M Before Key Bladder Data
Two ImmunityBio directors sold $1.12M in shares at $10.50–$10.75 in early October, at prices now 32–35% above the stock's current $7.95, weeks before November trial data for bladder cancer therapy Ank
Directors Sell $1.1M Above Market Before Anktiva Data
NEW YORK, November 3 —
Two directors at ImmunityBio, Inc. (IBRX) sold a combined $1.12 million in shares at $10.50, $10.75 in early October, at prices now 32-35% above the stock's current $7.95, just weeks before November trial data that management says could expand Anktiva's use in bladder cancer treatment.
- Cohen sold 81,056 shares at $10.50; Simon sold 25,000 at $10.75; zero insider purchases in 90 days.
- TTM revenue grew 93.9% to ~$170 million, driven by Anktiva's ongoing commercial launch.
- Net debt ~$870 million; trailing operating cash burn $281 million; short interest at 30.7% of float.
Exercise-and-Sell, Days Before the Data
ImmunityBio develops Anktiva, an immunotherapy approved for BCG-unresponsive non-muscle invasive bladder cancer, a market where treatment options narrow sharply after BCG failure. TTM revenue grew 93.9% to $170 million as the launch found traction. On October 2, director Cheryl Cohen exercised 55,979 options at $2.98 and sold 81,056 shares at $10.50 on the same day, a classic exercise-and-sell per Form 4 filings. Director Barry Simon sold 25,000 shares at $10.75 three days later. Both exits came in 32-35% above the current market, and no insider purchased shares in the 90-day window.
A Balance Sheet That Makes the Exit Look Rational
The stock's retreat to $7.95, a 12% drop in October alone against a 1.1% decline for the XBI biotech ETF, reflects balance sheet reality. ImmunityBio carries $1.23 billion in long-term debt against $360 million in cash, a net debt position of roughly $870 million, while trailing operating cash burn reached $281 million. Running a discounted cash flow analysis on a company with negative $187 million in free cash flow requires growth assumptions that dwarf the current trajectory. The August quarter EPS of -$0.22 against consensus of -$0.08 was the worst miss in the observed four-quarter history and the second consecutive shortfall after two prior beats.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IBRX | $8.4B | n/a | +282.2% |
| IOVA | $3.6B | n/a | +340.7% |
| SMMT | $11.8B | n/a | -15.4% |
| SLS | $1.7B | n/a | +415.1% |
| RXRX | $2.3B | n/a | -23.4% |
| VKTX | $3.4B | n/a | -22.5% |
November Decides Which Read Was Right
ImmunityBio secured an expanded Anktiva approval in October, per news filings, and expects bladder cancer trial results this month that management says could support earlier use in the treatment continuum. A favorable readout would reframe the director exits as routine liquidity harvested at a fair price; an adverse result invites a less charitable reading of their October timing. The thesis breaks if November data supports label expansion and the EPS trajectory stabilizes; it holds if the company's cash burn persists against a tightening balance sheet. Run the free ImmunityBio, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did ImmunityBio directors sell before trial data?
Two directors sold $1.12M in shares at $10.50, $10.75 in early October, occurring just weeks before November trial data. The sales were at prices now 32-35% above the stock's current level, with no insider purchases in the prior 90 days.
What is Anktiva used for?
Anktiva is an immunotherapy approved for BCG-unresponsive non-muscle invasive bladder cancer, a market where treatment options narrow sharply after BCG failure. Revenue grew 93.9% TTM to $170M as the drug's launch found traction.
When are the trial results coming?
ImmunityBio expects bladder cancer trial results in November. Management says these results could support earlier use of Anktiva in the treatment continuum, potentially expanding the drug's approved label.
What is ImmunityBio's financial position?
ImmunityBio carries $1.23B in long-term debt against $360M in cash, resulting in net debt of roughly $870M. The company faces $281M in trailing operating cash burn and reported August quarter EPS of –$0.22 versus consensus –$0.08, marking the worst miss in four quarters.
Two ImmunityBio directors sold $1.12 million in IBRX shares at $10.50–$10.75 in early October — prices that now sit well above the stock's current $7.95 level — just weeks before the company expects pivotal Anktiva bladder cancer trial results in November that could expand where the drug is used in treatment.